Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | XOMA |
---|---|---|
09:32 ET | 482 | 30.45 |
10:08 ET | 200 | 29.99 |
11:09 ET | 100 | 30 |
11:12 ET | 201 | 29.99 |
12:12 ET | 100 | 30.14 |
12:14 ET | 100 | 30.26 |
12:28 ET | 100 | 30.1 |
12:48 ET | 200 | 30.1 |
12:53 ET | 100 | 30.155 |
01:13 ET | 400 | 29.98 |
01:20 ET | 400 | 30.235 |
01:26 ET | 105 | 30.295 |
01:36 ET | 200 | 30.1 |
02:00 ET | 258 | 30.1 |
02:12 ET | 200 | 30.2 |
02:27 ET | 299 | 30.1 |
02:32 ET | 901 | 30.1 |
02:41 ET | 295 | 30.025 |
02:52 ET | 100 | 30.11 |
02:54 ET | 100 | 30 |
03:33 ET | 2000 | 30.1 |
03:46 ET | 361 | 30.1 |
03:48 ET | 600 | 30 |
03:50 ET | 400 | 29.85 |
03:53 ET | 100 | 29.8 |
04:00 ET | 3748 | 30.07 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
XOMA Royalty Corp | 354.3M | -9.8x | --- |
Northwest Biotherapeutics Inc | 367.2M | -4.5x | --- |
Prime Medicine Inc | 356.5M | -1.4x | --- |
enGene Holdings Inc | 339.1M | -1.6x | --- |
Q32 Bio Inc | 329.4M | -3.6x | --- |
Jasper Therapeutics Inc | 327.6M | -4.6x | --- |
XOMA Royalty Corporation is a biotechnology royalty aggregator. The Company’s royalty aggregator business is primarily focused on early to mid-stage clinical assets, primarily in Phase I and II, with significant commercial sales potential that are licensed to larger pharmaceutical partners. The Company has a portfolio of economic rights and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The Company's royalty portfolio includes OJEMDA (tovorafenib), JNJ-63723283 (cetrelimab), RZ358, arimoclomol, mezagitamab (TAK-079), acimtamig (AFM13), AB054, ficlatuzumab (AV-299), COM902, vosaroxin, aldoxorubicin, INCAGN02385, INCAGN02390, MNPR-101, PBF-680, PBF-677, PBF-999, PBF-1129, PBF-1650, RZ402, DSUVIA (sufentanil sublingual tablet), IXINITY [coagulation factor IX (recombinant)], CMP-001 (vidutolimod), NTM-1631, NTM-1634, NTM-1633, NTM-1632, NIR178, MK-4830, AFM24, INCAGN01949, AB101, and CFZ533 (iscalimab).
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $354.3M |
---|---|
Revenue (TTM) | $21.6M |
Shares Outstanding | 11.8M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.86 |
EPS | $-3.06 |
Book Value | $7.72 |
P/E Ratio | -9.8x |
Price/Sales (TTM) | 16.4 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -154.31% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.